HanAll Advancing Novel Dry Eye Contender Despite Mixed Top-Line
First Phase III Trial Misses Primary Endpoint
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.
